Idronoxil Suppository NOX66

Drug Overview

Idronoxil Suppository NOX66 is a specifically engineered rectal suppository formulation of idronoxil — a synthetic isoflavone derivative developed by Australian company Noxopharm Limited. While idronoxil itself has been studied in oral and intravenous forms for over two decades, NOX66 represents a purpose-built pharmaceutical evolution of the compound, designed to solve a critical clinical problem: although oral and intravenous forms of idronoxil have been well tolerated, early formulations were hampered by limited bioavailability.

NOX66 consists of idronoxil formulated in a fatty base and surfactant, with each suppository containing 400 mg idronoxil. By bypassing first-pass liver metabolism through rectal delivery, NOX66 achieves significantly higher and more consistent drug exposure — making it the formulation of choice for all current clinical trials of idronoxil.

• Generic Name: Idronoxil Suppository NOX66
• US Brand Name: Veyonda (investigational; Noxopharm Limited)
• Drug Class: ENOX2 Inhibitor / Synthetic Isoflavone Analog / Radiosensitizer / Chemosensitizer / Targeted Therapy
• Route of Administration: Rectal suppository (self-administered)
• FDA Approval Status: Not FDA-approved. NOX66 is the first clinical study formulation to assess idronoxil delivered as a rectal suppository in patients with refractory solid tumors. It is actively under investigation across multiple phase I/II trials including the LuPIN, DARRT, and CEP-1 programs.

What Is It and How Does It Work? (Mechanism of Action)

NOX66 delivers idronoxil rectally to bypass the liver’s first-pass metabolism — a process that was previously destroying much of the drug before it could reach the tumor. Once absorbed through the rectal mucosa into systemic circulation, idronoxil exerts its anti-cancer effects through three interconnected mechanisms:

ENOX2 Inhibition — Cancer-Selective Targeting: Idronoxil selectively binds to ENOX2 (External NADH Oxidase 2) — an enzyme expressed preferentially on cancer cell surfaces. The relatively lower dependence of nontumor cells on ENOX2 activity accounts for the low level of toxicity of idronoxil reported in animal toxicology studies and human clinical studies. This selectivity is what gives NOX66 its favorable safety profile even in heavily pretreated, end-stage patients.

Restoring Apoptosis: Idronoxil targets dysregulated prosurvival pathways mediated via Akt, FLIP, and XIAP in cancer cells, restoring caspase-mediated apoptosis. In drug-resistant tumors, these proteins act like survival shields. NOX66 dismantles these shields, allowing the cancer cell’s own programmed self-destruction machinery to function — a mechanism that most conventional chemotherapy drugs have failed to reactivate.

Radiosensitization and Chemosensitization: Idronoxil has been shown to sensitize cancer cells to a range of cytotoxic agents, and in particular to potently sensitize platinum-resistant ovarian cancer cells. Further studies have demonstrated that idronoxil also possesses antiangiogenic properties. By combining NOX66 with radiation or radioligand therapy, clinicians can achieve superior tumor destruction at doses that would otherwise be insufficient — a critical advantage in patients whose disease no longer responds to standard treatments.

FDA Approved Clinical Indications

Oncological Uses (Under Clinical Investigation — Not FDA-Approved):

• Metastatic Castration-Resistant Prostate Cancer (mCRPC) — in combination with 177Lu-PSMA-617 radioligand therapy (LuPIN trial) and with external beam radiotherapy (DARRT trial)
• Refractory Solid Tumors — in combination with carboplatin across multiple tumor types including ovarian, lung, and colorectal cancers (CEP-1 trial)
• Breast Cancer and Non-Small Cell Lung Cancer (NSCLC) — under investigation in phase 1b/2a expansion cohorts (NCT04957290)

Non-Oncological Uses:

• There are no approved or formally investigated non-oncological indications for NOX66 at this time.

Dosage and Administration Protocols

Patients were divided into 2 dose cohorts. Cohort 1 (n=8) received 1 suppository daily (400 mg) and cohort 2 (n=11) received 2 suppositories daily (800 mg) for 14 consecutive days followed by 7 days of rest. In combination radioligand trials, the dosing window is tied to the injection schedule. There was no dose modification of NOX66 based on body weight except where the patient exceeded 100 kg, in which case the dose could be increased up to double at the discretion of the investigator.

Clinical Efficacy and Research Results

NOX66’s most significant clinical data comes from two landmark trials. In the CEP-1 phase Ia/b study — the first-ever clinical trial of idronoxil as a rectal suppository — 19 patients with refractory solid tumors were enrolled. NOX66 was well tolerated at 400 mg and 800 mg as monotherapy and combined with carboplatin. The safety profile justifies continuation of the NOX66 clinical research program. The efficacy findings are encouraging in terms of the chemosensitizing potential of NOX66 in refractory solid tumors.

In the larger LuPIN phase I/II trial, all men received up to 6 cycles of 177Lu-PSMA-617 at 6-week intervals in combination with one of three doses of NOX66 (400, 800, and 1,200 mg). NOX66 was administered via suppository on days 1–10 after each 177Lu-PSMA-617 injection. Among the 56 enrolled end-stage mCRPC patients — all of whom had failed multiple prior therapies including docetaxel, abiraterone, and enzalutamide — 86% demonstrated a reduction in PSA level, 61% achieved a PSA reduction of at least 50%, median overall survival was 19.7 months, and 30% survived beyond 2 years. These are striking outcomes in a population typically expected to survive less than 12 months on available third-line therapies.

Safety Profile and Side Effects

Black Box Warning: There is no FDA Black Box Warning for NOX66, as it is not FDA-approved. The favorable safety profile of NOX66 provides reassurance to justify continuation of clinical research.

Common Side Effects (>10%):

• Anal Irritation — the most formulation-specific adverse effect; reported in 38% of LuPIN patients; generally grade 1 and managed with topical emollients before and after insertion
• Fatigue — mild (grade 1–2); consistent across all study cohorts; attributed to combined effects of NOX66 and co-administered radiation or radioligand therapy
• Anemia — with only anemia considered to be possibly related to NOX66 in the CEP-1 safety analysis; monitor hemoglobin before each cycle
• Nausea — mild and transient; managed with standard antiemetics

Serious Adverse Events:

• Animal studies with oral or intravenous dose formulations have been unable to determine the maximum tolerated dose — and consistent with this, no maximum tolerated dose was identified with NOX66 up to 1,200 mg daily in the LuPIN expansion cohort
• Thrombocytopenia: Previously observed with IV idronoxil formulations due to the cyclodextrin excipient; this side effect is not observed with the NOX66 suppository formulation
• Embryo-Fetal Toxicity: Theoretical risk based on the apoptosis-activating mechanism; effective contraception is required for patients of reproductive potential

Management Strategies:

• For anal irritation: apply topical emollients before each suppository insertion; consider dose interruption if grade 2 or higher irritation develops
• For anemia: check hemoglobin before each treatment cycle; provide transfusion support as clinically indicated
• For nausea: administer prophylactic antiemetics 30 minutes before daily suppository use if needed

Connection to Stem Cell and Regenerative Medicine

NOX66’s ENOX2-targeting mechanism provides a clinically meaningful advantage in the context of stem cell preservation. Because ENOX2 is expressed predominantly on cancer cell surfaces — and healthy tissues, including bone marrow stem cells, express the closely related but functionally distinct ENOX1 isoform — NOX66 largely spares the hematopoietic stem cell niche. This selectivity makes NOX66 uniquely compatible with multi-cycle radioligand therapies such as 177Lu-PSMA-617, which depend on intact bone marrow reserve for safe re-dosing. Current research is investigating whether NOX66’s radiosensitizing properties can enhance the anti-tumor efficacy of targeted alpha therapy and next-generation radioligand agents — a strategy that could extend its role across a much broader range of solid tumors.

Disclaimer: These studies regarding NOX66, ENOX2 selectivity, and combination use with radioligand therapies are still evolving and are not yet applicable to practical or professional clinical scenarios. While ENOX2 targeting may offer a theoretical advantage for tumor selectivity, the discussion regarding proven hematopoietic stem-cell sparing, routine compatibility with repeated radioligand dosing, or confirmed benefit across a broad solid-tumor range remains exploratory and should be interpreted cautiously.

Patient Management and Practical Recommendations

Pre-Treatment Tests:

• PSA level and complete blood count (CBC) — baseline and before each cycle
• 68Ga-PSMA PET/CT scan — required for radioligand combination eligibility assessment
• Liver function tests (LFTs) and kidney function panel (eGFR/creatinine)
• Testosterone level to confirm castration-resistant status in prostate cancer patients
• Pregnancy test for all women of childbearing age

Precautions During Treatment:

• Blood counts and PSA must be monitored before each 6-week treatment cycle
• Patients must follow the specific suppository administration instructions provided by the trial team
• NOX66 is only accessible through participation in an approved clinical trial

Do’s and Don’ts:

• DO self-administer the NOX66 suppository at the same time each day during the assigned dosing window
• DO apply a topical emollient before insertion to minimize local irritation
• DO report any significant rectal discomfort, bleeding, or unusual pain to your care team promptly
• DON’T use NOX66 outside of an approved and supervised clinical trial program
• DON’T miss any scheduled radioligand therapy or chemotherapy appointments — timing with NOX66 is clinically essential
• DON’T become pregnant during treatment — the apoptotic mechanism carries a theoretical fetal harm risk

Legal Disclaimer

The information in this guide is for educational purposes only and does not constitute medical advice, diagnosis, or a treatment recommendation. Idronoxil Suppository NOX66 (Veyonda) is an investigational drug that is not approved by the US Food and Drug Administration (FDA) or any major regulatory authority for routine clinical use. It is currently available only through participation in approved clinical trials. All treatment decisions must be made in consultation with a qualified oncologist or licensed healthcare professional with full knowledge of the patient’s complete medical history. This content does not replace official investigational protocol documentation or professional medical judgment.